268 related articles for article (PubMed ID: 31324230)
1. Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China.
Zhang J; Sun W; Lin J; Tian Y; Ma L; Zhang L; Zhu Y; Qiu W
BMC Infect Dis; 2019 Jul; 19(1):645. PubMed ID: 31324230
[TBL] [Abstract][Full Text] [Related]
2. Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience.
Alkadi MM; Abuhelaiqa EA; Elshirbeny MF; Hamdi AF; Fituri OM; Asim M; Alkaabi SR; Derbala MF; Jarman ME; Ashour AM; Nauman A; Al Maslamani YK; Butt AA; Al-Malki HA
Immun Inflamm Dis; 2021 Mar; 9(1):246-254. PubMed ID: 33264509
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.
Maghrabi HME; Elmowafy AY; Refaie AF; Elbasiony MA; Shiha GE; Rostaing L; Bakr MA
Int Urol Nephrol; 2019 Dec; 51(12):2295-2304. PubMed ID: 31531807
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal.
Weigert A; Querido S; Carvalho L; Lebre L; Chagas C; Matias P; Birne R; Nascimento C; Jorge C; Adragão T; Bruges M; Machado D
Transplant Proc; 2018 Apr; 50(3):743-745. PubMed ID: 29661427
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
Mansour M; Hill L; Kerr J
Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C Treatment in Chronic Kidney Disease Patients: The Kidney Disease Improving Global Outcomes Perspective.
Jadoul M; Martin P
Blood Purif; 2017; 43(1-3):206-209. PubMed ID: 28114144
[TBL] [Abstract][Full Text] [Related]
9. Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients.
Goel A; Bhadauria DS; Kaul A; Prasad N; Gupta A; Sharma RK; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 Mar; 36(2):137-140. PubMed ID: 28345112
[TBL] [Abstract][Full Text] [Related]
10. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
[TBL] [Abstract][Full Text] [Related]
11. Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial.
Reese PP; Abt PL; Blumberg EA; Van Deerlin VM; Bloom RD; Potluri VS; Levine M; Porrett P; Sawinski D; Nazarian SM; Naji A; Hasz R; Suplee L; Trofe-Clark J; Sicilia A; McCauley M; Gentile C; Smith J; Niknam BA; Bleicher M; Reddy KR; Goldberg DS
Ann Intern Med; 2018 Sep; 169(5):273-281. PubMed ID: 30083748
[TBL] [Abstract][Full Text] [Related]
12. Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
Pischke S; Polywka S; Proske VM; Lang M; Jordan S; Nashan B; Lohse AW; Sterneck M
Transpl Infect Dis; 2016 Feb; 18(1):141-5. PubMed ID: 26485543
[TBL] [Abstract][Full Text] [Related]
13. Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era.
Devresse A; Delire B; Lazarus JV; Kabamba B; De Meyer M; Mourad M; Buemi A; Darius T; Cambier JF; Goffin E; Jadoul M; Kanaan N
Transplant Proc; 2020 Apr; 52(3):815-822. PubMed ID: 32143864
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver-kidney transplant recipients.
Nookala AU; Crismale J; Schiano T; Te H; Ahn J; Robertazzi S; Rodigas C; Satoskar R; Kc M; Hassan M; Smith C
Clin Transplant; 2018 Mar; 32(3):e13198. PubMed ID: 29323755
[TBL] [Abstract][Full Text] [Related]
15. Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study.
Gendia M; Lampertico P; Alfieri CM; D'Ambrosio R; Gandolfo MT; Campise MR; Fabrizi F; Messa P
Transpl Int; 2019 May; 32(5):493-501. PubMed ID: 30580473
[TBL] [Abstract][Full Text] [Related]
16. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
[TBL] [Abstract][Full Text] [Related]
17. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
[TBL] [Abstract][Full Text] [Related]
18. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
Friebus-Kardash J; Gäckler A; Kribben A; Witzke O; Wedemeyer H; Treckmann J; Herzer K; Eisenberger U
Transpl Infect Dis; 2019 Oct; 21(5):e13146. PubMed ID: 31306562
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness and safety of direct-acting antivirals for the treatment of hepatitis C virus in kidney and liver transplant recipients: experience of a large transplant center in Brazil.
Pacheco LS; Ventura PE; Kist R; Garcia VD; Meinerz G; Tovo CV; Cantisani GPC; Zanotelli ML; Mucenic M; Keitel E
Rev Inst Med Trop Sao Paulo; 2023; 65():e59. PubMed ID: 38055377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
